Lung & Respiratory Disease Clinical Trials Update: Week 13, 2026

Published March 29, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Pragmatic Evaluation of Respiratory Distress Syndrome Treatment in Africa

This Phase 4 trial is focused on a new, less invasive surfactant treatment for respiratory distress syndrome in premature infants. The study is particularly important because it is being conducted in multiple African countries, where access to advanced medical care may be limited. If this treatment proves safe and effective, it could offer a safer and more accessible option to help preterm babies survive and recover in low-resource settings.

Randomized Trial of Sedative Choice for Intubation

This completed Phase 4 study compared two sedative drugs, ketamine and etomidate, in adults with acute respiratory failure who require emergency intubation. With over 2300 patients enrolled across several US hospitals, the trial aimed to identify which sedative causes fewer heart and blood pressure problems during the procedure. The results may help guide doctors in choosing safer sedation options for critically ill patients.

Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) Therapy

This Phase 3 trial is testing a new injection treatment called GZR18 for obese adults with moderate to severe obstructive sleep apnea who do not use or cannot tolerate the standard positive airway pressure therapy. Conducted in China, this study could provide an alternative treatment for people struggling with sleep apnea who need options beyond traditional devices. Results are expected after one year of treatment.

Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma

This Phase 4 trial compares a combination inhaler treatment (FF/UMEC/VI) against usual inhaled corticosteroids and long-acting beta-2 agonists for adults with asthma that is not well controlled. The study involves multiple sites worldwide and aims to find a more effective treatment to improve symptoms for people whose asthma remains difficult to manage. Results will be available after 52 weeks of treatment.

Implementing a Scalable Smoke-free Home Intervention in Armenia and Georgia

This study tests a program designed to reduce exposure to secondhand tobacco smoke in homes in Armenia and Georgia. By promoting smoke-free environments, the trial hopes to improve respiratory health for people living with smokers. The intervention is now recruiting participants in the United States and plans to enroll 550 people to assess its effectiveness and potential for wider use.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.